AbbVie's Atogepant Hits Phase 3 Goals in Menstrual Migraine, Plans Global Filings
ABBV sits 32% above its 52-week low of $190.75.
Summary
AbbVie's atogepant (Qulipta) met primary and secondary endpoints in a Phase 3 trial for preventive treatment of menstrual migraine, reducing migraine days by 1.2 vs 0.4 for placebo. The company plans to submit data to health authorities worldwide, targeting an indication with no currently approved treatments. This expands the drug's label beyond its existing migraine prevention approval in 60 countries. The news follows AbbVie's recent $10.9B Apogee acquisition and positive CHMP opinion for Rinvoq, reinforcing its neuroscience pipeline momentum.
At the time of this announcement, ABBV was trading at $252.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $446B. The 52-week trading range was $190.75 to $267.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.